Drug Profile
CEB 1050
Latest Information Update: 15 Aug 2000
Price :
$50
*
At a glance
- Originator Vernalis Group
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Behavioural disorders
Most Recent Events
- 15 Aug 2000 Discontinued-II for Behavioural disorders in USA (Unknown route)
- 24 May 2000 Vanguard Medica is now called Vernalis Group
- 29 Feb 2000 Cerebrus Pharmaceuticals has been acquired by Vanguard Medica